HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Kevin J H Allen Selected Research

Radioimmunotherapy

12/2021Radioimmunotherapy Targeting IGF2R on Canine-Patient-Derived Osteosarcoma Tumors in Mice and Radiation Dosimetry in Canine and Pediatric Models.
11/2020Mechanistic Insights into Synergy between Melanin-Targeting Radioimmunotherapy and Immunotherapy in Experimental Melanoma.
8/2020Safety Evaluation of an Alpha-Emitter Bismuth-213 Labeled Antibody to (1→3)-β-Glucan in Healthy Dogs as a Prelude for a Trial in Companion Dogs with Invasive Fungal Infections.
1/2020Radioimmunotherapy of Blastomycosis in a Mouse Model With a (1→3)-β-Glucans Targeting Antibody.
9/2019Evaluation of novel highly specific antibodies to cancer testis antigen Centrin-1 for radioimmunoimaging and radioimmunotherapy of pancreatic cancer.
7/2019Comparative Radioimmunotherapy of Experimental Melanoma with Novel Humanized Antibody to Melanin Labeled with 213Bismuth and 177Lutetium.
1/2019Daratumumab-225Actinium conjugate demonstrates greatly enhanced antitumor activity against experimental multiple myeloma tumors.
1/2019Detection and targeting insulin growth factor receptor type 2 (IGF2R) in osteosarcoma PDX in mouse models and in canine osteosarcoma tumors.
10/2018Evaluation of N-Succinimidyl S-Acetylthioacetate Ligand for Radiolabeling of Humanized Antibodies with 188Rhenium.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Kevin J H Allen Research Topics

Disease

12Neoplasms (Cancer)
12/2021 - 11/2013
3Osteosarcoma (Osteogenic Sarcoma)
12/2021 - 01/2019
3Melanoma (Melanoma, Malignant)
11/2020 - 10/2018
2Parkinson Disease (Parkinson's Disease)
08/2021 - 12/2016
2Experimental Melanoma
11/2020 - 07/2019
2Virus Diseases (Viral Diseases)
08/2020 - 01/2020
1Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/2021
1Invasive Fungal Infections
08/2020
1Infections
01/2020
1Blastomycosis
01/2020
1Testicular Neoplasms (Testicular Cancer)
09/2019
1Pancreatic Neoplasms (Pancreatic Cancer)
09/2019
1Multiple Myeloma
01/2019
1Communicable Diseases (Infectious Diseases)
12/2018

Drug/Important Bio-Agent (IBA)

5AntibodiesIBA
05/2021 - 10/2018
4Radioisotopes (Radionuclides)IBA
11/2020 - 10/2018
4Melanins (Melanin)IBA
11/2020 - 10/2018
4Monoclonal AntibodiesIBA
08/2020 - 12/2018
2SynucleinsIBA
08/2021 - 12/2016
2Insulin (Novolin)FDA Link
05/2021 - 01/2019
2Indicators and Reagents (Reagents)IBA
07/2019 - 10/2018
2Immunoglobulin G (IgG)IBA
07/2019 - 10/2018
1Caffeine (No Doz)FDA LinkGeneric
08/2021
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
05/2021
1Proteins (Proteins, Gene)FDA Link
01/2021
1venetoclaxIBA
01/2021
1Pharmaceutical PreparationsIBA
01/2021
1lintuzumabIBA
01/2021
1Immune Checkpoint InhibitorsIBA
11/2020
1Chimeric Antigen ReceptorsIBA
09/2020
1Bismuth-213IBA
08/2020
1beta-GlucansIBA
01/2020
1AntigensIBA
09/2019
1daratumumabIBA
01/2019
1Therapeutic UsesIBA
01/2019
1Complement System Proteins (Complement)IBA
01/2019
1Growth Factor ReceptorsIBA
01/2019
1Chelating AgentsIBA
10/2018
1N-hydroxysuccinimide S-acetylthioacetate (SATA)IBA
10/2018
1Histones (Histone)IBA
11/2013
1Lysine (L-Lysine)FDA Link
11/2013

Therapy/Procedure

9Radioimmunotherapy
12/2021 - 10/2018
3Therapeutics
05/2021 - 08/2020
2Immunotherapy
11/2020 - 07/2019
1Cell- and Tissue-Based Therapy (Cell Therapy)
09/2020